Nov 2023: Pembrolizumab (Keytruda, Merck) was granted approval by the Food and Drug Administration (FDA) as a neoadjuvant treatment in combination with platinum-containing chemotherapy and as a post-surgical adjuvant treatment f..
The Food and Drug Administration (FDA) approved Encorafenib (Braftovi, Array BioPharma Inc., a wholly owned subsidiary of Pfizer) and binimetinib (Mektovi, Array BioPharma Inc.) in November 2023 as medicines that can be used to t..
ເດືອນສິງຫາ 2023: Pralsetinib (Gavreto, Genentech, Inc.) ໄດ້ຮັບການອະນຸມັດເປັນປົກກະຕິໂດຍອົງການອາຫານ ແລະຢາສໍາລັບຄົນເຈັບຜູ້ໃຫຍ່ທີ່ມີມະເຮັງປອດອັກເສບ metastatic RET fusion-positive non-small cell lung cancer (NSCLC), ຕາມການກຳນົດໂດຍ FDA..
ເດືອນກຸມພາ 2023: ສໍາລັບຂັ້ນຕອນ IB (T2a 4 cm), ຂັ້ນຕອນ II, ຫຼືຂັ້ນຕອນ IIIA ມະເຮັງປອດທີ່ບໍ່ແມ່ນຈຸລັງຂະຫນາດນ້ອຍ, ອົງການອາຫານ ແລະຢາ (FDA) ໄດ້ອະນຸມັດ pembrolizumab (Keytruda, Merck) ເປັນການປິ່ນປົວແບບເສີມຫຼັງຈາກການຜ່າຕັດ ແລະ chemoth ທີ່ອີງໃສ່ platinum. ..
November 2022: The combination of tremelimumab (Imjudo, AstraZeneca Pharmaceuticals), durvalumab (Imfinzi, AstraZeneca Pharmaceuticals), and platinum-based chemotherapy was approved by the Food and Drug Administration for adult pa..
November 2022: The combination of cemiplimab-rwlc (Libtayo, Regeneron Pharmaceuticals, Inc.) and platinum-based chemotherapy for adult patients with advanced non-small cell lung cancer (NSCLC) without EGFR, ALK, or ROS1 abnormalit..
August 2022: For adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation resulting in mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test, the Food..
August 2022: For adult patients with metastatic non-small cell lung cancer (NSCLC) whose tumours have a mutation resulting in mesenchymal-epithelial transition (MET) exon 14 skipping, as detected by an FDA-approved test, the Food..
ເດືອນມີນາ 2022: ໃນການຕັ້ງຄ່າ neoadjuvant, FDA ໄດ້ອະນຸມັດ nivolumab (Opdivo, Bristol-Myers Squibb Company) ໃນການປະສົມປະສານກັບການປິ່ນປົວດ້ວຍເຄມີບໍາບັດ platinum-doublet ສໍາລັບຄົນເຈັບຜູ້ໃຫຍ່ທີ່ມີມະເຮັງປອດທີ່ບໍ່ແມ່ນຈຸລັງຂະຫນາດນ້ອຍ (NSCLC).
Nov 2021: The Food and Drug Administration has approved atezolizumab (Tecentriq, Genentech, Inc.) for adjuvant treatment in patients with stage II to IIIA non-small cell lung cancer (NSCLC) whose tumours contain PD-L1 expression o..